Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability

Heart Rhythm

Volumn 8, Issue 11, 2011, Pages 1777-1785

  Malik, Marek ^a   Zhang, Joanne ^b   Johannesen, Lars ^b   Hnatkova, Katerina ^c   Garnett, Christine ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c St Paul's Cardiac Electrophysiology   (United Kingdom)

Author keywords

ECG measurement; Measurement reproducibility; Measurement stability; Positive control; QTc interval; Thorough QT study

Indexed keywords

MOXIFLOXACIN;

ACCURACY; ARTICLE; ASSAY; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; QUALITY CONTROL; REPRODUCIBILITY;

ANTI-ARRHYTHMIA AGENTS; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 80054978661     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2011.06.016     Document Type: Article

References (14)

1. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs Guidance to industry Fed Regist 70 2005 61134 61135
2. ICH Topic E14 The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions and answers (EMEA/CHMP/ICH/310133/2008) www.emea.europa.eu/pdfs/human/ich/31013308en.pdf
3. D.M. Bloomfield, J.T. Kost, and K. Ghosh The effect of moxifloxacin on QTc and implications for the design of thorough QT studies Clin Pharmacol Ther 84 2008 475 480
4. M. Malik, K. Hnatkova, A. Schmidt, and P. Smetana Electrocardiographic QTc changes due to moxifloxacin infusion J Clin Pharmacol 49 2009 674 683
5. J.A. Florian, C.W. Tornøe, R. Brundage, A. Parekh, and C.E. Garnett Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies J Clin Pharmacol 51 2011 1152 1162
6. L.K. Yan, J. Zhang, M.J. Ng, and Q. Dang Statistical characteristics of moxifloxacin-induced QTc effect J Biopharmaceut Stat 20 2010 497 507
7. M. Malik, J.O. Andreas, and K. Hnatkova Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine Clin Pharmacol Ther 84 2008 595 603
8. Zhang J. Thorough QT study design and baseline issues. DIA Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding. 2009 presentation.
9. V.N. Batchvarov, A. Ghuran, and P. Smetana QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability Am J Physiol Heart Circ Physiol 282 2002 H2356 H2363
10. P.M. Rautaharju, and Z.-M. Zhang Linearly scaled, rate-invariant normal limits for QT interval: Eight decades of incorrect application of power functions J Cardiovasc Electrophysiol 13 2002 1211 1218 (Pubitemid 36042717)
11. M. Malik, K. Hnatkova, A. Schmidt, and P. Smetana Accurately measured and properly heart-rate corrected QTc intervals show little daytime variability Heart Rhythm 5 2008 1424 1431
12. M. Malik, C.E. Garnett, and J. Zhang Thorough QT studies Questions and quandaries Drug Safety 33 2010 1 14
13. K. Hnatkova, P. Smetana, O. Toman, A. Bauer, G. Schmidt, and M. Malik Systematic comparisons of electrocardiographic morphology increase the precision of QT interval measurement Pacing Clin Electrophysiol 32 2009 119 130
14. C.E. Garnett, N. Beasley, and V.A. Bhattaram Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review J Clin Pharmacol 48 2008 13 18 (Pubitemid 350292272)